Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2019

25.10.2019 | Research Article

Preventability analysis of adverse drug reactions in a Jordanian hospital: a prospective observational study

verfasst von: Lama Al Damen, Iman Basheti

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background Adverse drug reactions remain to be an issue that compromise patient’s safety in Jordan and worldwide. In Jordan, an assessment of factors involved in preventability of adverse drug reactions has not been conducted previously. Objectives To describe the proportion of preventable adverse drug reactions, and the causes of hospital-related preventable adverse reactions in one Jordanian hospital. Methods A prospective observational study of 4 months duration conducted by clinical pharmacists in the hospital. Setting Surgical and medical wards in one Jordanian private hospital. Main outcome measure Proportions of admissions related to adverse drug reactions, proportions of preventable reactions and analysis of the factors involved in the preventable adverse drug reactions. Results Out of 350 admissions recorded during the study period, a total of 38 (10.8%) adverse reactions were detected. Among those, 29 (8.3%) were detected in the hospital and 9 (2.6%) were the cause of the hospital admission. Many (44.7%) of the adverse drug reactions were preventable (31.6% were probably preventable and 13.1% were definitely preventable). About half (55.3%) were unpreventable. Insufficient monitoring was involved in 29.4% of the preventable adverse reactions and inappropriate dosing and drug–drug interactions were independently responsible for 17.6% of the preventable adverse reactions. Conclusion A high proportion of the identified adverse drug reactions were found to be preventable. Insufficient monitoring and inappropriate dosing were the most important factors associated with preventable adverse drug reactions. Nationally, more focused efforts need to be stimulated to prevent preventable adverse drug reactions in hospitals.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Rawlins M, Thomson J. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991. p. 18–45. Rawlins M, Thomson J. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991. p. 18–45.
3.
Zurück zum Zitat Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38:437–53.CrossRef Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38:437–53.CrossRef
4.
Zurück zum Zitat Alomar M. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22:83–94.CrossRef Alomar M. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22:83–94.CrossRef
5.
Zurück zum Zitat Maxwell S. Rational prescribing: the principles of drug selection. Clin Med (Lond). 2016;16:459–64.CrossRef Maxwell S. Rational prescribing: the principles of drug selection. Clin Med (Lond). 2016;16:459–64.CrossRef
6.
Zurück zum Zitat Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56:935–41.CrossRef Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56:935–41.CrossRef
8.
Zurück zum Zitat Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, et al. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007;30:81–8.CrossRef Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, et al. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007;30:81–8.CrossRef
9.
Zurück zum Zitat Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12:280–5.CrossRef Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12:280–5.CrossRef
10.
Zurück zum Zitat Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice. Drug Saf. 2002;25:1035–44.CrossRef Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice. Drug Saf. 2002;25:1035–44.CrossRef
11.
Zurück zum Zitat Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRef Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRef
12.
Zurück zum Zitat Winterstein AG, Hatton RC, Gonzales-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reactions reports. Am J Health Syst Pharm. 2002;59:1742–9.CrossRef Winterstein AG, Hatton RC, Gonzales-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reactions reports. Am J Health Syst Pharm. 2002;59:1742–9.CrossRef
13.
Zurück zum Zitat Forster AJ, Worthington JR, Hawken S, Bourke M, Rubens F, Shojania K, et al. Using prospective clinical surveillance to identify adverse events in hospital. BMJ Qual Saf. 2011;20:756–63.CrossRef Forster AJ, Worthington JR, Hawken S, Bourke M, Rubens F, Shojania K, et al. Using prospective clinical surveillance to identify adverse events in hospital. BMJ Qual Saf. 2011;20:756–63.CrossRef
14.
Zurück zum Zitat Smits M, Zegers M, Groenewegen PP, Timmermans DR, Zwaan L, van der Wal G, Wagner C. Exploring the causes of adverse events in hospitals and potential prevention strategies. Qual Saf Health Care. 2010;19(5):e5.PubMed Smits M, Zegers M, Groenewegen PP, Timmermans DR, Zwaan L, van der Wal G, Wagner C. Exploring the causes of adverse events in hospitals and potential prevention strategies. Qual Saf Health Care. 2010;19(5):e5.PubMed
15.
Zurück zum Zitat Alsbou M. Incidence of adverse drug reactions in Alkarak Governmental Hospital: a pilot study. J Med. 2010;44(4):444–6. Alsbou M. Incidence of adverse drug reactions in Alkarak Governmental Hospital: a pilot study. J Med. 2010;44(4):444–6.
16.
Zurück zum Zitat Alsbou M, Alzubiedi S, Alzobi H, Samhadanah NA, Alsaraireh Y, Alrawashdeh O, et al. Adverse drug reactions (ADRs) experience at Al-Karak Teaching Hospital in Jordan. Int J Clin Pharm. 2015;37:1188–93.CrossRef Alsbou M, Alzubiedi S, Alzobi H, Samhadanah NA, Alsaraireh Y, Alrawashdeh O, et al. Adverse drug reactions (ADRs) experience at Al-Karak Teaching Hospital in Jordan. Int J Clin Pharm. 2015;37:1188–93.CrossRef
17.
Zurück zum Zitat Raut A, Patel PK, Patel CD, Pawar AK. Preventability, predictability and seriousness of adverse drug reactions amongst medicine inpatients in a teaching hospital: a prospective observational study. Int J Pharm Chem Sci. 2012;1:1293–9. Raut A, Patel PK, Patel CD, Pawar AK. Preventability, predictability and seriousness of adverse drug reactions amongst medicine inpatients in a teaching hospital: a prospective observational study. Int J Pharm Chem Sci. 2012;1:1293–9.
20.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRef Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRef
21.
Zurück zum Zitat Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting ADRs. Am J Hosp Pharm. 1992;49:2229–32.PubMed Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting ADRs. Am J Hosp Pharm. 1992;49:2229–32.PubMed
22.
Zurück zum Zitat Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMed Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMed
23.
Zurück zum Zitat Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a Department of General Medicine. Br J Clin Pharmacol. 1998;45:301–8.CrossRef Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a Department of General Medicine. Br J Clin Pharmacol. 1998;45:301–8.CrossRef
24.
Zurück zum Zitat Alhamid A, Zoe Aslanpour Z, Aljadhey H, Ghaleb M. Hospitalisation resulting from medicine-related problems in adult patients with cardiovascular diseases and diabetes in the United Kingdom and Saudi Arabia. Int J Environ Res Public Health. 2016;13:479.CrossRef Alhamid A, Zoe Aslanpour Z, Aljadhey H, Ghaleb M. Hospitalisation resulting from medicine-related problems in adult patients with cardiovascular diseases and diabetes in the United Kingdom and Saudi Arabia. Int J Environ Res Public Health. 2016;13:479.CrossRef
25.
Zurück zum Zitat Aljadhey H, Mahmoud MA, Ahmed Y, Sultana R, Zouein S, Alshanawani S, et al. Incidence of adverse drug events in public and private hospitals in Riyadh, Saudi Arabia: the (ADESA) prospective cohort study. BMJ Open. 2016;6(7):e010831.CrossRef Aljadhey H, Mahmoud MA, Ahmed Y, Sultana R, Zouein S, Alshanawani S, et al. Incidence of adverse drug events in public and private hospitals in Riyadh, Saudi Arabia: the (ADESA) prospective cohort study. BMJ Open. 2016;6(7):e010831.CrossRef
26.
Zurück zum Zitat Aljadhey H, Mahmoud MA, Mayet A, Alshaikh M, Ahmed Y, Murray MD, et al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care. 2013;25:648–55.CrossRef Aljadhey H, Mahmoud MA, Mayet A, Alshaikh M, Ahmed Y, Murray MD, et al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care. 2013;25:648–55.CrossRef
27.
Zurück zum Zitat Farcas A, Bucsa C, Sinpetrean A, Leucuta D, Mogosan C, Dumitrascu D, et al. Preventability analysis of adverse drug reactions detected in two internal medicine departments in Romania. Intern Emerg Med. 2014;9:187–93.CrossRef Farcas A, Bucsa C, Sinpetrean A, Leucuta D, Mogosan C, Dumitrascu D, et al. Preventability analysis of adverse drug reactions detected in two internal medicine departments in Romania. Intern Emerg Med. 2014;9:187–93.CrossRef
28.
Zurück zum Zitat Dequito AB, Mol PG, van Doormaal JE, Zaal RJ, van den Bemt PM, Haaijer-Ruskamp FM, et al. Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands. Drug Saf. 2011;34:1089–100.CrossRef Dequito AB, Mol PG, van Doormaal JE, Zaal RJ, van den Bemt PM, Haaijer-Ruskamp FM, et al. Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands. Drug Saf. 2011;34:1089–100.CrossRef
29.
Zurück zum Zitat Bates DW, Cullen DJ, Laird N. Incidence of adverse drug events and potential adverse drug events: implications for prevention. J Am Med Assoc. 1995;274(1):29–34.CrossRef Bates DW, Cullen DJ, Laird N. Incidence of adverse drug events and potential adverse drug events: implications for prevention. J Am Med Assoc. 1995;274(1):29–34.CrossRef
30.
Zurück zum Zitat Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60:1750–9.CrossRef Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60:1750–9.CrossRef
Metadaten
Titel
Preventability analysis of adverse drug reactions in a Jordanian hospital: a prospective observational study
verfasst von
Lama Al Damen
Iman Basheti
Publikationsdatum
25.10.2019
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2019
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00925-0

Weitere Artikel der Ausgabe 6/2019

International Journal of Clinical Pharmacy 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.